Acadia Pharmaceuticals' Remlifanserin Shows Favorable Setup Ahead of Phase 2 Data, RBC Says

MT Newswires Live03-24

Acadia Pharmaceuticals (ACAD) has a favorable risk-reward setup ahead of phase 2 data forremlifanserin, or ACP-204, in Alzheimer's disease psychosis, RBC Capital Markets said in a report Tuesday.

The firm said the drug has a 40% probability of success for a clinically meaningful response with a large $500 million plus market opportunity and significant potential for upside.

Preclinical data suggests that remlifanserin may be more potent than its predecessor, while suggesting the drug could have a wider therapeutic window, RBC analysts noted.

The firm said Acadia's existing commercial franchises, Nuplazid and Daybue, remain solid and continue to show signs of growth within the US.

RBC kept its price target on Acadia's stock at $30 and maintained its outperform rating.

Price: 20.83, Change: -0.16, Percent Change: -0.79

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621096982?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 23:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621096982","market":"sh","top_or_hot":-1,"title":"Acadia Pharmaceuticals' Remlifanserin Shows Favorable Setup Ahead of Phase 2 Data, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Acadia Pharmaceuticals (ACAD) has a favorable risk-reward setup ahead of phase 2 data forremlifanserin, or ACP-204, in Alzheimer's disease psychosis, RBC Capital Markets said in a report Tuesday.</p><p>The firm said the drug has a 40% probability of success for a clinically meaningful response with a large $500 million plus market opportunity and significant potential for upside.</p><p>Preclinical data suggests that remlifanserin may be more potent than its predecessor, while suggesting the drug could have a wider therapeutic window, RBC analysts noted.</p><p>The firm said Acadia's existing commercial franchises, Nuplazid and Daybue, remain solid and continue to show signs of growth within the US.</p><p>RBC kept its price target on Acadia's stock at $30 and maintained its outperform rating.</p><p>Price: 20.83, Change: -0.16, Percent Change: -0.79</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acadia Pharmaceuticals' Remlifanserin Shows Favorable Setup Ahead of Phase 2 Data, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcadia Pharmaceuticals' Remlifanserin Shows Favorable Setup Ahead of Phase 2 Data, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-24 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Acadia Pharmaceuticals (ACAD) has a favorable risk-reward setup ahead of phase 2 data forremlifanserin, or ACP-204, in Alzheimer's disease psychosis, RBC Capital Markets said in a report Tuesday.</p><p>The firm said the drug has a 40% probability of success for a clinically meaningful response with a large $500 million plus market opportunity and significant potential for upside.</p><p>Preclinical data suggests that remlifanserin may be more potent than its predecessor, while suggesting the drug could have a wider therapeutic window, RBC analysts noted.</p><p>The firm said Acadia's existing commercial franchises, Nuplazid and Daybue, remain solid and continue to show signs of growth within the US.</p><p>RBC kept its price target on Acadia's stock at $30 and maintained its outperform rating.</p><p>Price: 20.83, Change: -0.16, Percent Change: -0.79</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065171402.SGD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2621096982","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621096982","pubTimestamp":1774365281,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Acadia Pharmaceuticals  has a favorable risk-reward setup ahead of phase 2 data forremlifanserin, or ACP-204, in Alzheimer's disease psychosis, RBC Capital Markets said in a report Tuesday.The firm said the drug has a 40% probability of success for a clinically meaningful response with a large $500 million plus market opportunity and significant potential for upside.Preclinical data suggests that remlifanserin may be more potent than its predecessor, while suggesting the drug could have a wider therapeutic window, RBC analysts noted.The firm said Acadia's existing commercial franchises, Nuplazid and Daybue, remain solid and continue to show signs of growth within the US.RBC kept its price target on Acadia's stock at $30 and maintained its outperform rating.Price: 20.83, Change: -0.16, Percent Change: -0.79","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4080":"零售业房地产投资信托","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","ACAD":"阿卡迪亚","BK4139":"生物科技","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","AKR":"阿卡迪亚房地产信托","BK4231":"零售房地产信托"},"translate_title":"加拿大皇家银行表示，Acadia Pharmaceuticals的Remlifanserin在第二阶段数据之前显示出良好的设置","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKR":1.5,"ACAD":1},"content_text":"Acadia Pharmaceuticals (ACAD) has a favorable risk-reward setup ahead of phase 2 data forremlifanserin, or ACP-204, in Alzheimer's disease psychosis, RBC Capital Markets said in a report Tuesday.The firm said the drug has a 40% probability of success for a clinically meaningful response with a large $500 million plus market opportunity and significant potential for upside.Preclinical data suggests that remlifanserin may be more potent than its predecessor, while suggesting the drug could have a wider therapeutic window, RBC analysts noted.The firm said Acadia's existing commercial franchises, Nuplazid and Daybue, remain solid and continue to show signs of growth within the US.RBC kept its price target on Acadia's stock at $30 and maintained its outperform rating.Price: 20.83, Change: -0.16, Percent Change: -0.79","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621096982","isCrawlerRequest":true}